Vertex CEO takes Morgan Stanley analyst to task at conference

Vertex Pharmaceuticals ($VRTX) CEO Matthew Emmens didn't stick with the script at yesterday's Morgan Stanley Global Healthcare Conference. Armed with stellar early sales figures for Vertex's new hep C drug Incivek, Emmens scolded the investment bank's own analyst David Friedman, accusing him of failing to understand the company. Report

Suggested Articles

California CDMO JSR Life Sciences is building a new home for two subsidiaries as it hopes to enter the competitive biologics market.

Three facts about how distributors are managing in-demand inventory.

Novartis’ latest campaign with a celebrity dance partner asks people to bust a move to raise awareness around sickle cell anemia and therapy Adakveo.